• 1 January 1981
    • journal article
    • research article
    • Vol. 42  (11) , 1971-1974
Abstract
Chemotherapeutic doses of methotrexate (MTX) were encapsulated in as little as 1 ml of canine carrier erythrocytes. Carrier erythrocytes prepared by a dialysis technique contained more than 3.0 mg of MTX/ml of cells. In vivo pharmacokinetic studies indicated that most of the drug leaked from the circulating MTX-loaded erythrocytes. In dogs, glutaraldehyde treatment of MTX-loaded erythrocytes prevented drug leakage and targeted more than 50% of the drug to the liver. [This study serves as a basis for the treatment of metastatic liver disease in the dog.].